Company intelligence / Profile preview

Behyaar Sanaat Sepahan

Isfahan, Isfahan Province, Iran

Ownership: Private
Development stage: Commercial

Overview

Behyaar has developed safflower-derived cationic lipid nanoparticles effective for in vitro mRNA transfection with high cellular uptake (~72%) and low cytotoxicity. The technology is positioned as a promising platform for efficient mRNA delivery; further in vivo evaluation is needed.

Therapeutic areas: NephrologyInfectious Diseases
Modalities: Lipid nanoparticle delivery therapySmall molecule (e.g., silymarin, limonene)Protein (e.g., collagen, gelatin)Enzyme (e.g., protease enzyme)Natural product extracts (e.g., licorice extract)
Industry: Non-Drug Biotech

Partnerships

Razi Vaccine Research Institute – joint project on LNP-based nucleic acid therapeutics/vaccinesExport development partnerships with Zimbabwean medical sector

Beyond the preview

Go deeper on Behyaar Sanaat Sepahan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Behyaar Sanaat Sepahan.

Explore the full profile